Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores

MLA

Piera Gargiulo, et al. “Predicting Mortality and Adverse Events in Patients with Advanced Pancreatic Cancer Treated with Palliative Gemcitabine-Based Chemotherapy in a Multicentre Phase III Randomized Clinical Trial: The APC-SAKK Risk Scores.” Therapeutic Advances in Medical Oncology, vol. 11, Jan. 2019. EBSCOhost, https://doi.org/10.1177/1758835918818351.

APA

Piera Gargiulo, Daniel Dietrich, Richard Herrmann, György Bodoky, Thomas Ruhstaller, Werner Scheithauer, Bengt Glimelius, Simona Berardi, Sandro Pignata, & Peter Brauchli. (2019). Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores. Therapeutic Advances in Medical Oncology, 11. https://doi.org/10.1177/1758835918818351

Chicago

Piera Gargiulo, Daniel Dietrich, Richard Herrmann, György Bodoky, Thomas Ruhstaller, Werner Scheithauer, Bengt Glimelius, Simona Berardi, Sandro Pignata, and Peter Brauchli. 2019. “Predicting Mortality and Adverse Events in Patients with Advanced Pancreatic Cancer Treated with Palliative Gemcitabine-Based Chemotherapy in a Multicentre Phase III Randomized Clinical Trial: The APC-SAKK Risk Scores.” Therapeutic Advances in Medical Oncology 11 (January). doi:10.1177/1758835918818351.